CHEK2 and cancer: When excluding genes not clearly associated with pancreatic cancer, the mutation detection rate is 10.7%, which is similar to previous reports.2, 4, 16, 17, 18, 19 Although the significance of germline variants in BRIP1, CHEK2, and monoallelic MUTYH within the context of PDAC remains uncertain, the implications with regard to other hereditary cancer risks remain clinically meaningful and demonstrate the utility of wider gene panel testing.